In vitro immune responses of human PBMCs against Candida albicans reveals fungal and leucocyte phenotypes associated with fungal persistence.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
10 04 2020
Historique:
received: 26 07 2019
accepted: 30 03 2020
entrez: 12 4 2020
pubmed: 12 4 2020
medline: 15 12 2020
Statut: epublish

Résumé

Although there is a growing understanding of immunity against Candida albicans, efforts need to be pursued in order to decipher the cellular mechanisms leading to an uncontrolled immune response that eventually oppose disease eradication. We describe here significant intra- and inter-subject variations in immune response patterns of major human leucocyte subsets following an in vitro challenge with C. albicans clinical isolates. We also observed that there are Candida isolate-dependent changes in leucocyte phenotypes. Through a combination of multiple fungal growth and flow cytometric measurements, coupled to the tSNE algorithm, we showed that significant proliferation differences exist among C. albicans isolates, leading to the calculation of a strain specific persistent index. Despite substantial inter-subject differences in T cells and stability of myeloid cells at baseline, our experimental approach highlights substantial immune cell composition changes and cytokine secretion profiles after C. albicans challenge. The significant secretion of IL-17 by CD66+ cells, IFN-γ and IL-10 by CD4+ T cells 2 days after C. albicans challenge was associated with fungal control. Fungal persistence was associated with delayed secretion of IFN-γ, IL-17, IL-4, TNF-α and IL-10 by myeloid cells and IL-4 and TNF-α secretion by CD4+ and CD8+ T cells. Overall, this experimental and analytical approach is available for the monitoring of such fungal and human immune responses.

Identifiants

pubmed: 32277137
doi: 10.1038/s41598-020-63344-6
pii: 10.1038/s41598-020-63344-6
pmc: PMC7148345
doi:

Substances chimiques

Cytokines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6211

Références

Dadar, M. et al. Candida albicans - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control - An update. Microb Pathog 117, 128–138 (2018).
pubmed: 29454824 doi: 10.1016/j.micpath.2018.02.028 pmcid: 29454824
Underhill, D. M. & Pearlman, E. Immune Interactions with Pathogenic and Commensal Fungi: A Two-Way Street. Immunity 43, 845–858 (2015).
pubmed: 26588778 pmcid: 4865256 doi: 10.1016/j.immuni.2015.10.023
Perez, J. C., Kumamoto, C. A. & Johnson, A. D. Candida albicans commensalism and pathogenicity are intertwined traits directed by a tightly knit transcriptional regulatory circuit. Plos Biol 11, e1001510 (2013).
pubmed: 23526879 pmcid: 3601966 doi: 10.1371/journal.pbio.1001510
Allert, S. et al. Candida albicans-Induced Epithelial Damage Mediates Translocation through Intestinal Barriers. MBio 9 (2018).
Richardson, J. P., Moyes, D. L., Ho, J. & Naglik, J. R. Candida innate immunity at the mucosa. Semin. Cell Dev. Biol., https://doi.org/10.1016/j.semcdb.2018.02.026 (2018).
Romani, L. Immunity to fungal infections. Nat. Rev. Immunol. 11, 275–288 (2011).
pubmed: 21394104 doi: 10.1038/nri2939 pmcid: 21394104
Bitar, D. et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis 20, 1149–1155 (2014).
pubmed: 24960557 pmcid: 4073874 doi: 10.3201/eid2007.140087
Pfaller, M. A. et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS ONE 9, e101510 (2014).
pubmed: 24991967 pmcid: 4081561 doi: 10.1371/journal.pone.0101510
Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N. & Castanheira, M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 55, 561–566 (2011).
pubmed: 21115790 doi: 10.1128/AAC.01079-10 pmcid: 21115790
Segal, B. H. et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 47, 674–683 (2008).
pubmed: 18637757 pmcid: 2671230 doi: 10.1086/590566
GAFFI. Global action fund for fungal infection; http://www.gaffi.org/ GAFFI (2014).
Yapar, N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag 10, 95–105 (2014).
pubmed: 24611015 pmcid: 3928396 doi: 10.2147/TCRM.S40160
Arendrup, M. C. Epidemiology of invasive candidiasis. Curr Opin Crit Care 16, 445–452 (2010).
pubmed: 20711075 doi: 10.1097/MCC.0b013e32833e84d2 pmcid: 20711075
Wang, X., van de Veerdonk, F. L. & Netea, M. G. Basic Genetics and Immunology of Candida Infections. Infect Dis Clin North Am 30, 85–102 (2016).
pubmed: 26897063 doi: 10.1016/j.idc.2015.10.010 pmcid: 26897063
Netea, M. G., Joosten, L. A. B., van der Meer, J. W. M., Kullberg, B.-J. & van de Veerdonk, F. L. Immune defence against Candida fungal infections. Nat. Rev. Immunol. 15, 630–642 (2015).
pubmed: 26388329 doi: 10.1038/nri3897 pmcid: 26388329
Borghi, M. et al. Pathogenic NLRP3 Inflammasome Activity during Candida Infection Is Negatively Regulated by IL-22 via Activation of NLRC4 and IL-1Ra. Cell Host Microbe 18, 198–209 (2015).
pubmed: 26269955 doi: 10.1016/j.chom.2015.07.004 pmcid: 26269955
Martinez-Alvarez, J. A., Perez-Garcia, L. A., Flores-Carreon, A. & Mora-Montes, H. M. The immune response against Candida spp. and Sporothrix schenckii. Rev Iberoam Micol 31, 62–66 (2014).
pubmed: 24252829 doi: 10.1016/j.riam.2013.09.015 pmcid: 24252829
Hope, W., Natarajan, P. & Goodwin, L. Invasive fungal infections. Clin Med (Lond) 13, 507–510 (2013).
doi: 10.7861/clinmedicine.13-5-507
Kim, M. H. et al. Neutrophil survival and c-kit(+)-progenitor proliferation in Staphylococcus aureus-infected skin wounds promote resolution. Blood 117, 3343–3352 (2011).
pubmed: 21278352 pmcid: 3069674 doi: 10.1182/blood-2010-07-296970
Gow, N. A., van de Veerdonk, F. L., Brown, A. J. & Netea, M. G. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol 10, 112–122 (2012).
doi: 10.1038/nrmicro2711
Jabra-Rizk, M. A. et al. Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework. Infect Immun 84, 2724–2739 (2016).
pubmed: 27430274 pmcid: 5038058 doi: 10.1128/IAI.00469-16
Aoun, J. et al. Caseating granulomas in cutaneous leishmaniasis. PLoS Negl Trop Dis 8, e3255 (2014).
pubmed: 25340702 pmcid: 4207691 doi: 10.1371/journal.pntd.0003255
Girgis, N. M. et al. Ly6C(high) monocytes become alternatively activated macrophages in schistosome granulomas with help from CD4+ cells. PLoS Pathog 10, e1004080 (2014).
pubmed: 24967715 pmcid: 4072804 doi: 10.1371/journal.ppat.1004080
Subbian, S. et al. Lesion-Specific Immune Response in Granulomas of Patients with Pulmonary Tuberculosis: A Pilot Study. PLoS ONE 10, e0132249 (2015).
pubmed: 26133981 pmcid: 4489805 doi: 10.1371/journal.pone.0132249
Heninger, E. et al. Characterization of the Histoplasma capsulatum-induced granuloma. J Immunol 177, 3303–3313 (2006).
pubmed: 16920971 pmcid: 2748851 doi: 10.4049/jimmunol.177.5.3303
De Luca, A. et al. IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis. PLoS Pathog 9, e1003486 (2013).
pubmed: 23853597 pmcid: 3708875 doi: 10.1371/journal.ppat.1003486
Legrand, F. et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis 46, 696–702 (2008).
pubmed: 18230039 doi: 10.1086/527390 pmcid: 18230039
Singh, H. R., Singh, N. G. & Singh, T. B. Estimation of CD4+ and CD8+ T-lymphocytes in human immunodeficiency virus infection and acquired immunodeficiency syndrome patients in Manipur. Indian J Med Microbiol 25, 126–132 (2007).
pubmed: 17582182 doi: 10.4103/0255-0857.32718 pmcid: 17582182
Misme-Aucouturier, B., Albassier, M., Alvarez-Rueda, N. & Le Pape, P. Specific Human and Candida Cellular Interactions Lead to Controlled or Persistent Infection Outcomes during Granuloma-Like Formation. Infect Immun 85, e00807–16 (2017).
pubmed: 27799331 doi: 10.1128/IAI.00807-16 pmcid: 27799331
Alvarez-Rueda, N. et al. First human model of in vitro Candida albicans persistence within granuloma for the reliable study of host-fungi interactions. PLoS ONE 7, e40185 (2012).
pubmed: 22768252 pmcid: 3387014 doi: 10.1371/journal.pone.0040185
Schönherr, F. A. et al. The intraspecies diversity of C. albicans triggers qualitatively and temporally distinct host responses that determine the balance between commensalism and pathogenicity. Mucosal Immunol 10, 1335–1350 (2017).
pubmed: 28176789 doi: 10.1038/mi.2017.2 pmcid: 28176789
Misme-Aucouturier, B. et al. Double positive CD4+CD8+ T cells are part of the adaptive immune response against Candida albicans. Hum. Immunol. 80, 999–1005 (2019).
pubmed: 31561914 doi: 10.1016/j.humimm.2019.09.008 pmcid: 31561914
Chen, E. et al. Fungal-Host Interaction: Curcumin Modulates Proteolytic Enzyme Activity of Candida albicans and Inflammatory Host Response In Vitro. Int J Dent 2018, 2393146 (2018).
pubmed: 30186325 pmcid: 6114239 doi: 10.1155/2018/2393146
Rapala-Kozik, M. et al. Extracellular proteinases of Candida species pathogenic yeasts. Mol Oral Microbiol 33, 113–124 (2018).
pubmed: 29139623 doi: 10.1111/omi.12206 pmcid: 29139623
Trevino-Rangel, R. J. et al. Phenotypical characterization and molecular identification of clinical isolates of Candida tropicalis. Rev Iberoam Micol 35, 17–21 (2018).
pubmed: 29287631 doi: 10.1016/j.riam.2017.05.002 pmcid: 29287631
Hirakawa, M. P. et al. Genetic and phenotypic intra-species variation in Candida albicans. Genome Res. 25, 413–425 (2015).
pubmed: 25504520 pmcid: 4352881 doi: 10.1101/gr.174623.114
Marakalala, M. J. et al. Differential adaptation of Candida albicans in vivo modulates immune recognition by dectin-1. PLoS Pathog 9, e1003315 (2013).
pubmed: 23637604 pmcid: 3630191 doi: 10.1371/journal.ppat.1003315
MacCallum, D. M. et al. Property differences among the four major Candida albicans strain clades. Eukaryotic Cell 8, 373–387 (2009).
pubmed: 19151328 pmcid: 2653250 doi: 10.1128/EC.00387-08
Netea, M. G. & Maródi, L. Innate immune mechanisms for recognition and uptake of Candida species. Trends Immunol 31, 346–353 (2010).
pubmed: 20705510 doi: 10.1016/j.it.2010.06.007 pmcid: 20705510
Amulic, B., Cazalet, C., Hayes, G. L., Metzler, K. D. & Zychlinsky, A. Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol. 30, 459–489 (2012).
pubmed: 22224774 doi: 10.1146/annurev-immunol-020711-074942 pmcid: 22224774
Fradin, C. et al. Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood. Mol Microbiol 56, 397–415 (2005).
pubmed: 15813733 doi: 10.1111/j.1365-2958.2005.04557.x pmcid: 15813733
Hünniger, K. et al. A virtual infection model quantifies innate effector mechanisms and candida albicans immune escape in human blood. PLoS Comput Biol 10, e1003479 (2014).
pubmed: 24586131 pmcid: 3930496 doi: 10.1371/journal.pcbi.1003479
Ngo, L. Y. et al. Inflammatory monocytes mediate early and organ-specific innate defense during systemic candidiasis. J Infect Dis 209, 109–119 (2014).
pubmed: 23922372 doi: 10.1093/infdis/jit413 pmcid: 23922372
Romani, L. et al. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol 158, 5349–5356 (1997).
pubmed: 9164955 pmcid: 9164955
Leonardi, I. et al. CX3CR1+ mononuclear phagocytes control immunity to intestinal fungi. Science 359, 232–236 (2018).
pubmed: 29326275 pmcid: 5805464 doi: 10.1126/science.aao1503
Zielinski, C. E. et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 484, 514–518 (2012).
pubmed: 22466287 doi: 10.1038/nature10957 pmcid: 22466287
Griffiths, S. J. et al. Age-associated increase of low-avidity cytomegalovirus-specific CD8+ T cells that re-express CD45RA. J Immunol 190, 5363–5372 (2013).
pubmed: 23636061 pmcid: 3736312 doi: 10.4049/jimmunol.1203267
van de Veerdonk, F. L., Joosten, L. A. & Netea, M. G. The interplay between inflammasome activation and antifungal host defense. Immunol. Rev. 265, 172–180 (2015).
pubmed: 25879292 doi: 10.1111/imr.12280 pmcid: 25879292
van de Veerdonk, F. L. et al. Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37. Front Microbiol 5, 762 (2014).
pubmed: 25620965 pmcid: 25620965
van de Veerdonk, F. L. et al. Redundant role of TLR9 for anti-Candida host defense. Immunobiology 213, 613–620 (2008).
pubmed: 18950591 doi: 10.1016/j.imbio.2008.05.002 pmcid: 18950591
Jacobsen, I. D., Luttich, A., Kurzai, O., Hube, B. & Brock, M. In vivo imaging of disseminated murine Candida albicans infection reveals unexpected host sites of fungal persistence during antifungal therapy. J Antimicrob Chemother 69, 2785–2796 (2014).
pubmed: 24951534 doi: 10.1093/jac/dku198 pmcid: 24951534
Lionakis, M. S. et al. Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLoS Pathog 8, e1002865 (2012).
pubmed: 22916017 pmcid: 3420964 doi: 10.1371/journal.ppat.1002865
Wozniok, I. et al. Induction of ERK-kinase signalling triggers morphotype-specific killing of Candida albicans filaments by human neutrophils. Cell Microbiol 10, 807–820 (2008).
pubmed: 18034864 doi: 10.1111/j.1462-5822.2007.01086.x pmcid: 18034864
Hünniger, K. et al. A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a. J Immunol 194, 1199–1210 (2015).
pubmed: 25539819 doi: 10.4049/jimmunol.1401845 pmcid: 25539819
Lionakis, M. S. & Netea, M. G. Candida and host determinants of susceptibility to invasive candidiasis. PLoS Pathog 9, e1003079 (2013).
pubmed: 23300452 pmcid: 3536687 doi: 10.1371/journal.ppat.1003079
Taylor, P. R., Leal, S. M., Sun, Y. & Pearlman, E. Aspergillus and Fusarium corneal infections are regulated by Th17 cells and IL-17-producing neutrophils. J Immunol 192, 3319–3327 (2014).
pubmed: 24591369 pmcid: 4020181 doi: 10.4049/jimmunol.1302235
Huppler, A. R., Verma, A. H., Conti, H. R. & Gaffen, S. L. Neutrophils Do Not Express IL-17A in the Context of Acute Oropharyngeal Candidiasis. Pathogens 4, 559–572 (2015).
pubmed: 26213975 pmcid: 4584272 doi: 10.3390/pathogens4030559
Huang, W., Na, L., Fidel, P. L. & Schwarzenberger, P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 190, 624–631 (2004).
pubmed: 15243941 doi: 10.1086/422329 pmcid: 15243941
Bacher, P. et al. Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans. Cell 176, 1340–1355.e15 (2019).
pubmed: 30799037 doi: 10.1016/j.cell.2019.01.041 pmcid: 30799037
Mengesha, B. G. & Conti, H. R. The Role of IL-17 in Protection against Mucosal Candida Infections. J Fungi (Basel) 3, 52 (2017).
doi: 10.3390/jof3040052
Conti, H. R. & Gaffen, S. L. IL-17-Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans. J Immunol 195, 780–788 (2015).
pubmed: 26188072 pmcid: 4507294 doi: 10.4049/jimmunol.1500909
Bär, E., Whitney, P. G., Moor, K., Reise Sousa, C. & Leibundgut-Landmann, S. IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity 40, 117–127 (2014).
pubmed: 24412614 doi: 10.1016/j.immuni.2013.12.002 pmcid: 24412614
Atarashi, K. et al. Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells. Cell 163, 367–380 (2015).
pubmed: 26411289 pmcid: 4765954 doi: 10.1016/j.cell.2015.08.058
Hu, S. et al. IL-17 Production of Neutrophils Enhances Antibacteria Ability but Promotes Arthritis Development During Mycobacterium tuberculosis Infection. EBioMedicine 23, 88–99 (2017).
pubmed: 28821374 pmcid: 5605331 doi: 10.1016/j.ebiom.2017.08.001
Hernandez-Santos, N. & Gaffen, S. L. Th17 cells in immunity to Candida albicans. Cell Host Microbe 11, 425–435 (2012).
pubmed: 22607796 pmcid: 3358697 doi: 10.1016/j.chom.2012.04.008
Romani, L. & Puccetti, P. Controlling pathogenic inflammation to fungi. Expert Rev Anti Infect Ther 5, 1007–1017 (2007).
pubmed: 18039084 doi: 10.1586/14787210.5.6.1007 pmcid: 18039084
Romani, L. & Puccetti, P. Protective tolerance to fungi: the role of IL-10 and tryptophan catabolism. Trends Microbiol 14, 183–189 (2006).
pubmed: 16517165 doi: 10.1016/j.tim.2006.02.003 pmcid: 16517165
Reales-Calderon, J. A., Aguilera-Montilla, N., Corbi, A. L., Molero, G. & Gil, C. Proteomic characterization of human proinflammatory M1 and anti-inflammatory M2 macrophages and their response to Candida albicans. Proteomics 14, 1503–1518 (2014).
pubmed: 24687989 doi: 10.1002/pmic.201300508 pmcid: 24687989
Vogel, D. Y. et al. Human macrophage polarization in vitro: maturation and activation methods compared. Immunobiology 219, 695–703 (2014).
pubmed: 24916404 doi: 10.1016/j.imbio.2014.05.002 pmcid: 24916404
Ambarus, C. A., Noordenbos, T., de Hair, M. J., Tak, P. P. & Baeten, D. L. Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis. Arthritis Res. Ther. 14, R74 (2012).
pubmed: 22494514 pmcid: 3446447 doi: 10.1186/ar3796
Schraufstatter, I. U., Zhao, M., Khaldoyanidi, S. K. & Discipio, R. G. The chemokine CCL18 causes maturation of cultured monocytes to macrophages in the M2 spectrum. Immunology 135, 287–298 (2012).
pubmed: 22117697 pmcid: 3372745 doi: 10.1111/j.1365-2567.2011.03541.x
Szymczak, W. A. & Deepe, G. S. J. The CCL7-CCL2-CCR2 axis regulates IL-4 production in lungs and fungal immunity. J Immunol 183, 1964–1974 (2009).
pubmed: 19587014 pmcid: 2743878 doi: 10.4049/jimmunol.0901316
Echenique-Rivera, H. et al. Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog 7, e1002027 (2011).
pubmed: 21589640 pmcid: 3088726 doi: 10.1371/journal.ppat.1002027
Deslouches, B. et al. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob Agents Chemother 49, 3208–3216 (2005).
pubmed: 16048927 pmcid: 1196285 doi: 10.1128/AAC.49.8.3208-3216.2005
Tena, G. N. et al. Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus and its relationship to T cell function. J Infect Dis 187, 1544–1551 (2003).
pubmed: 12721934 doi: 10.1086/374799 pmcid: 12721934

Auteurs

Nidia Alvarez-Rueda (N)

Nantes Université, CHU de Nantes, Cibles et médicaments des infections et du cancer, IICiMed, EA 1155, F-44000, Nantes, France. nidia.alvarez-rueda@univ-nantes.fr.

Célia Rouges (C)

Nantes Université, CHU de Nantes, Cibles et médicaments des infections et du cancer, IICiMed, EA 1155, F-44000, Nantes, France.

Adel Touahri (A)

Nantes Université, CHU de Nantes, Cibles et médicaments des infections et du cancer, IICiMed, EA 1155, F-44000, Nantes, France.

Barbara Misme-Aucouturier (B)

Nantes Université, CHU de Nantes, Cibles et médicaments des infections et du cancer, IICiMed, EA 1155, F-44000, Nantes, France.

Marjorie Albassier (M)

Nantes Université, CHU de Nantes, Cibles et médicaments des infections et du cancer, IICiMed, EA 1155, F-44000, Nantes, France.

Patrice Le Pape (PL)

Nantes Université, CHU de Nantes, Cibles et médicaments des infections et du cancer, IICiMed, EA 1155, F-44000, Nantes, France. patrice.le-pape@univ-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH